Andrew Tsai
Stock Analyst at Jefferies
(0.69)
# 3,900
Out of 4,944 analysts
22
Total ratings
30%
Success rate
-26.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Buy | $40 → $35 | $19.33 | +81.07% | 3 | Jul 24, 2025 | |
| STOK Stoke Therapeutics | Initiates: Buy | $30 | $15.51 | +93.42% | 1 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Buy | $70 | $49.82 | +40.51% | 1 | Jul 14, 2025 | |
| VRNA Verona Pharma | Maintains: Buy | $95 → $110 | $105.24 | +4.52% | 1 | Jun 11, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Hold | $29 → $2.5 | $3.15 | -20.63% | 2 | May 28, 2025 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $200 | $108.96 | +83.55% | 1 | Apr 7, 2025 | |
| BEKE KE Holdings | Maintains: Overweight | $19 → $27 | $18.39 | +46.86% | 2 | Mar 19, 2025 | |
| RLMD Relmada Therapeutics | Upgrades: Buy | $3.5 → $13 | $0.58 | +2,160.87% | 2 | Sep 17, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $35 | $15.89 | +120.26% | 1 | Jul 2, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $33 | $3.15 | +945.99% | 1 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $0.2 → $15 | $3.03 | +395.05% | 2 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $3 | $1.11 | +171.49% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $3 | $0.39 | +669.23% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $4.12 | +555.34% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $37.52 | -38.69% | 1 | Jun 1, 2020 |
Sarepta Therapeutics
Jul 24, 2025
Maintains: Buy
Price Target: $40 → $35
Current: $19.33
Upside: +81.07%
Stoke Therapeutics
Jul 18, 2025
Initiates: Buy
Price Target: $30
Current: $15.51
Upside: +93.42%
BridgeBio Pharma
Jul 14, 2025
Initiates: Buy
Price Target: $70
Current: $49.82
Upside: +40.51%
Verona Pharma
Jun 11, 2025
Maintains: Buy
Price Target: $95 → $110
Current: $105.24
Upside: +4.52%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Hold
Price Target: $29 → $2.5
Current: $3.15
Upside: -20.63%
Axsome Therapeutics
Apr 7, 2025
Initiates: Buy
Price Target: $200
Current: $108.96
Upside: +83.55%
KE Holdings
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $18.39
Upside: +46.86%
Relmada Therapeutics
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $0.58
Upside: +2,160.87%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $15.89
Upside: +120.26%
Alto Neuroscience
Feb 27, 2024
Initiates: Buy
Price Target: $33
Current: $3.15
Upside: +945.99%
Dec 7, 2023
Upgrades: Buy
Price Target: $0.2 → $15
Current: $3.03
Upside: +395.05%
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $1.11
Upside: +171.49%
Jun 23, 2022
Downgrades: Hold
Price Target: $32 → $3
Current: $0.39
Upside: +669.23%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $4.12
Upside: +555.34%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $37.52
Upside: -38.69%